bluebird bio Inc (NASDAQ:BLUE) announced that theEuropean Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for LentiGlobin drug product in …
Maxim analyst Jason McCarthy weighed in with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the gene-therapy-product maker announced that a pivotal phase III study …
bluebird bio Inc (NASDAQ:BLUE) has initiated a Phase III trial (HB-207) for its pipeline drug LentiGlobin, designed to treat transfusion-dependent beta-thalassemia patients with …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, …
Piper Jaffray reduced the price target to $95, while reiterating Overweight
Leerink Swann analyst, Michael Schmidt, reiterates his Outperform rating on bluebird bio Inc (NASDAQ:BLUE) after the company reported its 2Q16 financial results. The analyst couples his …
Analyst Gena Wang of Jefferies commented on bluebird bio Inc (NASDAQ:BLUE) following management meetings on programs for pipeline gene therapies LentiGlobin, Lenti-D, and …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
A meeting with bluebird bio Inc’s (NASDAQ:BLUE) leadership last week validified Dane Leone’s, an analyst at BTIG, confidence in the company. The meeting …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies …
